SLC13A3i

SLC13A3i may be used in studies for its role in inhibiting the uptake of itaconate in tumor cells, which may help understand tumor immune evasion mechanisms and improve cancer treatment strategies. It may also be used to explore metabolic pathways related to integrin functions and their impact on cellular processes, particularly in cancer research.

A cell-permeable solute carrier family 13-member 3 (SLC13A3) inhibitor (SLC13A3i) targets the SLC13A3 transporter to block the oncometabolite itaconate uptake, thereby reducing tumor ferroptosis resistance and enhancing immune responses in SLC13A3+ tumors. By disrupting the NRF2-SLC7A11 pathway, SLC13A3i sensitizes tumor cells to ferroptosis and increases CD8+ T cell infiltration in the tumor microenvironment. Preclinical studies show robust efficacy of SLC13A3i in both in vitro (1-5 mM) and in vivo (10-20 mg/kg, i.p.) models, especially when combined with anti-PD-L1 immunotherapy, resulting in slowed tumor progression and improved immune cell engagement. With a favorable safety profile and metabolic stability, SLC13A3i emerges as a promising immunometabolic therapeutic candidate for treating resistant cancers.